Laue, C.
Ballance, S.
Knutsen, S. H.
Papazova, E.
Soeth, E.
Pannenbeckers, A.
Schrezenmeir, J.
Funding for this research was provided by:
Norges Forskningsråd (243871, 243871, 243871, 243871, 243871, 243871)
Article History
Received: 23 November 2018
Revised: 7 March 2019
Accepted: 26 March 2019
First Online: 10 April 2019
Compliance with ethical standards
: The study was conducted in line with the principles of the Declaration of Helsinki (32), the guidelines for Good Clinical Practice (ICH E6) (33), and in accordance with European and National regulatory requirements. All clinical data were collected at the study site of the Clinical Research Center Kiel GmbH. Supplementary information is available at EJCN’s website.
: SB, SHK, JS: Are inventors of a patent on this matter [CitationRef removed] and hold shares (as does CL) in Glucozero GmBH. This company is currently licensing the patent from Nofima AS (full-time employer of SB and SHK). The remaining authors declare that they have no conflict of interest.